abstract |
The present invention relates to interacting and often synergistically minimizing adverse events and reducing metabolic disorders and their main components in a significant and sustained manner. The present invention relates to a method for treating a patient suffering from metabolic syndrome, type 2 diabetes, obesity or pre-diabetes, in the central nervous system of a patient, in particular in the hypothalamus of the central nervous system. Increasing the activity ratio of dopaminergic neurons to noradrenergic neurons. [Selection figure] None |